Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats relapsing forms of multiple sclerosis (MS). Sold as Leustatin, Mavenclad. Every FDA application for this active ingredient: 2 branded and 6 generic.
As of Nov 14, 2026, FDA lists 8 applications for Cladribine (sold as Leustatin, Mavenclad), first approved Feb 26, 1993, with 0 new uses approved and 1 published complete response letter.
First approved: Feb 26, 1993
Applications: 8
New uses approved: 0
Complete response letters: 1
Medicare spending, 2025: $327M
First approved in the EU: Apr 14, 2004
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
LeustatinA drug with a new additional dosage indicated for the treatment of recurrent, relapsing, or refractory indolent B-cell non-Hodgkin's lymphoma including… · Janssen Pharmaceutical K.K. · Mar 24, 2009
Clinical Trials
54 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Hikma
Fresenius Kabi USA
Apotex